Search Results for treatment

Polaris Rx Chosen by Bristol Myers Squibb to Distribute ZENBEXUS™, the First FDA-Approved CELMoD Treatment for Multiple Myeloma

Polaris Rx Selected by Bristol Myers Squibb to Dispense First-in-Class Multiple Myeloma Therapy ZENBEXUS (Iberdomide) Polaris Rx has announced that it has been selected by Bristol Myers Squibb (BMS) to dispense ZENBEXUS™ (iberdomide), the first cereblon E3 ligase modulator (CELMoD)…

Read MorePolaris Rx Chosen by Bristol Myers Squibb to Distribute ZENBEXUS™, the First FDA-Approved CELMoD Treatment for Multiple Myeloma

REDEMPLO® (Plozasiran) Offers New Triglyceride-Lowering Treatment Option for Adults with FCS in England and Wales

Arrowhead Pharmaceuticals’ REDEMPLO Gains NICE Recommendation for NHS Treatment of Familial Chylomicronaemia Syndrome in England and Wales Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) has received a positive funding recommendation from the National Institute for Health and Care Excellence (NICE), creating a new…

Read MoreREDEMPLO® (Plozasiran) Offers New Triglyceride-Lowering Treatment Option for Adults with FCS in England and Wales

Dong-A ST Highlights Preclinical Potential of Topical Icotrokinra for Psoriasis Treatment

Dong-A ST Presents Preclinical Findings Supporting Topical Icotrokinra Development for Psoriasis Dong-A ST Co., Ltd., a South Korean pharmaceutical company led by President and CEO Jae-hoon Jeong, has presented preclinical research findings demonstrating the potential of a topical formulation of…

Read MoreDong-A ST Highlights Preclinical Potential of Topical Icotrokinra for Psoriasis Treatment

ViiV Healthcare Highlights Five-Year U.S. Real-World Evidence Supporting Cabenuva’s Long-Term Effectiveness and Treatment Persistence

ViiV Healthcare Reports Five-Year Real-World Evidence Supporting Long-Term Cabenuva Effectiveness in HIV Treatment ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, has announced new real-world evidence from the OPERA observational cohort evaluating…

Read MoreViiV Healthcare Highlights Five-Year U.S. Real-World Evidence Supporting Cabenuva’s Long-Term Effectiveness and Treatment Persistence

Edwards Lifesciences Receives FDA Approval for PASCAL Precision System to Expand Treatment Options for Tricuspid Valve Disease

Edwards Lifesciences Receives FDA Approval for PASCAL Precision System for Tricuspid Valve Repair Edwards Lifesciences Corporation (NYSE: EW), a global developer of patient-focused innovations for structural heart disease, has announced that the U.S. Food and Drug Administration (FDA) has approved…

Read MoreEdwards Lifesciences Receives FDA Approval for PASCAL Precision System to Expand Treatment Options for Tricuspid Valve Disease

Shionogi Presents IDWeek 2026 U.S. Real-World Data Showing Improved Outcomes with Early Fetroja®/Fetcroja® Treatment in Respiratory Infections

Shionogi to Present New Fetroja®/Fetcroja® Data at IDWeek 2026 Highlighting Early Treatment Outcomes and Activity Against Drug-Resistant Gram-Negative Bacteria Shionogi & Co., Ltd., headquartered in Osaka, Japan, and led by Chief Executive Officer Isao Teshirogi, Ph.D., will present new clinical…

Read MoreShionogi Presents IDWeek 2026 U.S. Real-World Data Showing Improved Outcomes with Early Fetroja®/Fetcroja® Treatment in Respiratory Infections

Algia Pharma Reports Positive IND-Enabling Study Results for AlgiaPak® Non-Opioid Acute Pain Treatment

Algia Pharma Completes IND-Enabling Toxicology Study for AlgiaPak, Advancing Non-Opioid Acute Pain Treatment Toward Clinical Trials Algia Pharma, LLC has announced the successful completion of an Investigational New Drug (IND)-enabling preclinical toxicology study for AlgiaPak®, a hospital-grade multimodal pain management…

Read MoreAlgia Pharma Reports Positive IND-Enabling Study Results for AlgiaPak® Non-Opioid Acute Pain Treatment

Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter to Halve Treatment Time

Johnson & Johnson Launches Shockwave C2 Aero Fly Coronary IVL Catheter to Cut Treatment Time in Half Johnson & Johnson (NYSE: JNJ) has announced the U.S. launch of its Shockwave C2 Aero Fly Coronary Intravascular Lithotripsy (IVL) Catheter, a next-generation…

Read MoreJohnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter to Halve Treatment Time

FDA Approves Genentech’s Tecentriq Combination for Stage III Colon Cancer Adjuvant Treatment

Genentech’s Tecentriq Receives FDA Approval for Adjuvant Treatment of Stage III dMMR Colon Cancer Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and…

Read MoreFDA Approves Genentech’s Tecentriq Combination for Stage III Colon Cancer Adjuvant Treatment

Study Links Avoiding Sweets During Antibiotic Treatment to Better Gut Microbiome Health

City of Hope Study Links High Sugar Intake to Greater Antibiotic-Related Gut Microbiome Disruption Researchers at City of Hope, a major cancer research and treatment organization, have reported new findings suggesting that consuming higher amounts of sugar during antibiotic treatment…

Read MoreStudy Links Avoiding Sweets During Antibiotic Treatment to Better Gut Microbiome Health

MoneyStack Raises Funding to Integrate Financial Crisis Care Into Behavioral Health Treatment

MoneyStack Raises $1 Million to Integrate Financial Counseling Into Behavioral Healthcare MoneyStack, a financial counseling platform designed for behavioral healthcare, has raised $1 million in new funding to expand access to specialized financial support for people experiencing mental health conditions,…

Read MoreMoneyStack Raises Funding to Integrate Financial Crisis Care Into Behavioral Health Treatment